

K011372

AESCULAP®, Inc

510(k) Premarket Notification
Safil® Quick Synthetic Absorbable Surgical Suture

AUG - 1 2001

VII. 510(k) Summary

In accordance with the Safe Medical Devices Act (SMDA) of 1990 and Title 21 of the Code of Federal Regulations Part 807 (21 CFR §807), and in particular §807.92, the following summary of safety and effectiveness information is provided:

A. Submitted for

AESCULAP®, Inc.

3773 Corporate Parkway

Center Valley, Pennsylvania 18034

Telephone: (610) 797-9300

Contact: Joyce Thomas, Director of Regulatory Affairs & Quality Assurance

Date Prepared: May 2, 2001

B. Device Name

Trade or Proprietary Name: *Safil® Quick Synthetic Absorbable
Surgical Suture*

Common or Usual Name: Absorbable Poly(Glycolide/L-lactide)
Surgical Suture

Classification Name: Absorbable Poly(Glycolide/L-lactide)
Surgical Suture

C. Predicate Devices

The subject device is substantially equivalent to the following predicate devices:

- *Safil® Synthetic Absorbable Surgical Suture* (AESCULAP®, Inc.)
- *VICRYL® Rapid Synthetic Absorbable Surgical Suture* (Ethicon, Inc.)

D. Device Description

The subject device is an absorbable, flexible multifilament suture thread which is supplied sterile. It is composed of synthetic polyglycolic acid polymer, and is indicated for soft tissue approximation where only short term wound support is required, or where rapid resorption of the suture would be beneficial. It will be offered undyed, and dyed with the FDA approved colorant D&C Green No. 6 in accordance with Title 21 CFR, §74.3206. It will be available uncoated, and coated with an absorbable magnesium stearate-based coating. It will also be available with or without standard needles attached.

E. Intended Use

Safil® Quick Synthetic Absorbable Surgical Suture is indicated for use in general soft tissue approximation, including ophthalmic procedures, but not in cardiovascular or neurological procedures.

F. Comparison to Predicate Devices

Safil® Quick Synthetic Absorbable Surgical Suture is composed of 100% polyglycolic acid, a material identical to that comprising the predicate *Safil®* suture, and equivalent to the material comprising the predicate VICRYL® Rapid device. Further, the subject device is offered undyed, and dyed with the same colorant as the *Safil®* predicate device, that being D&C Green No. 6 at a concentration that conforms to the requirements of Title 21 CFR, §74.3206.

The subject device has the same design as do the *Safil®* and VICRYL® Rapid predicate devices, being a sterile, flexible thread available in a braided multifilament form in sizes 8-0 and larger, and as a monofilament in sizes 9-0 and 10-0. The sutures are offered uncoated, or in braided sizes, may be treated with an absorbable magnesium stearate-based coating to enhance handling characteristics and reduce tissue drag.

The subject suture is offered in a variety of lengths and a range of diameters conforming with the requirements of U. S. Pharmacopeia (U.S.P.) XXIV, and is offered with or without one of a selection of standard needles attached. Further, as is the case with the predicate devices, the subject device conforms in all respects to the requirements of the Official Monograph for Absorbable Surgical Suture in U.S.P. XXIV, including <861> *Sutures -- Diameter*, <871> *Sutures -- Needle Attachment*, and <881> *Tensile Strength*.

Physical properties of the subject device are substantially equivalent to those of the *Safil®* and VICRYL® Rapid predicate devices, including suture diameter, knot pull tensile strength, and needle attachment strength, among others.

The subject device is manufactured in a manner typical of the industry and equivalent to that used to produce predicate devices, wherein: Polyglycolic acid polymer is synthesized via condensation reaction; the polymer is melt extruded and spun to form fine filaments of specified diameter and are then drawn to enhance tensile properties; the fibers are then braided to produce multifilament suture fiber, coated, and then cut to length and attached to needles. Given that the subject device is made from the same material, and in the same manner, as the *Safil®* predicate device, the subject device has the same or equivalent chemical characteristics, biocompatibility, and/or *in vivo* performance properties as do the predicate devices. The subject device is packaged and sterilized in the same or equivalent manner, and has the same or equivalent labeling claims as do the predicate devices, including indications, contraindications, warnings, cautions and precautions.

G. Summary of Non-Clinical Tests

Non-clinical testing conducted on the subject device to demonstrate its substantial equivalence to predicate devices included physical testing for all parameters identified above, sterilization validation and evaluation of sterilant residues, and shelf-life testing. Testing conducted by the manufacturer included testing of physical properties to prove conformance to the requirements of U.S.P., *in vitro* and *in vivo* biosafety studies, and implant studies in animals to demonstrate rates of tensile strength and mass loss.

H. Summary of Clinical Tests

(Not applicable)

I. Conclusions of Non-Clinical and Clinical Tests

The results of all testing demonstrated the substantial equivalence, if not superiority, of the subject device to one or more predicate devices.



AUG - 1 2001

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Aesculap, Inc.
c/o Mr. Steve Reitzler, RAC
13221 Maricotte Place
San Diego, California 92130

Re: K011372

Trade/Device Name: AESCULAP®, Inc. Safil® Quick Synthetic Absorbable Suture
Regulation Number: 878.4493
Regulatory Class: II
Product Code: GAM
Dated: May 2, 2001
Received: May 4, 2001

Dear Mr. Reitzler:


We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

Handwritten signature of Celia M. Witten in black ink.

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative
and Neurological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

V. Draft Labeling

A. Indications for Use

510(k) Number (if known): K011372

Device Name: Safil® Quick Synthetic Absorbable Surgical Suture

Indications for Use:

Safil® Quick suture is indicated for use in general soft tissue approximation, including ophthalmic procedures, but not in cardiovascular or neurological procedures.


Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ☒

OR

Over-The-Counter Use ☐

(Per 21 CFR 801.109)



(Division Sign-Off)

Division of General, Restorative
and Neurological Devices

510(k) Number K011372